PCSK9 inhibitors in clinical practice: Novel directions and new experiences

PCSK9 inhibitors in clinical practice: Novel directions and new experiences

Background: In randomized clinical trials, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a favorable tolerability and safety profile. Our purpose is to provide real-world data regarding the indications, efficacy...

Full description

Bibliographic Details
Main Authors: Loukianos S. Rallidis, Ioannis Skoumas, Evangelos N. Liberopoulos, Charalambos Vlachopoulos, Estela Kiouri, Iosif Koutagiar, Georgia Anastasiou, Nikolaos Kosmas, Moses S. Elisaf, Dimitrios Tousoulis, Efstathios Iliodromitis
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Hellenic Journal of Cardiology
Subjects:
familial hypercholesterolaemia
proprotein convertase subtilisin/kexin type 9 inhibitors
statin intolerant patient
Online Access:http://www.sciencedirect.com/science/article/pii/S1109966619302763

Internet

http://www.sciencedirect.com/science/article/pii/S1109966619302763

Similar Items